Condition: Charcot-Marie-Tooth Disease Type 1A · Sponsor: Assistance Publique Hopitaux De Marseille
This is a 2-year follow-up study of a cohort of 35 CMT1A patients and 20 healthy volunteers. The main objective is identifying prognostic markers for CMT1A using multi-omics analysis. The study is recruiting subjects between the ages of 10 and 30. The most common inherited neuropathy is Charcot-Marie-Tooth disease type 1A (CMT1A), caused by a duplication of the gene expressing PMP22. CMT1A patients develop symptoms in early childhood with variable progression and there is no established therapy until now. Therapy must start in childhood, before peripheral nerves degenerate. However, we lack easily obtainable biomarkers in early disease stages. In CMT-MODs, we will identify disease and prognostic biomarkers in young CMT1A patients.
This description comes directly from the study's public registry record.
Shahram ATTARIAN, PU-PH · 04 91 38 65 79 · shahram.attarian@ap-hm.fr
Etienne FORTANIER, MD · 04 91 38 65 79 · etienne.fortanier@ap-hm.fr
Always discuss trial participation with your own doctor first.
| Assistance Publique - Hôpitaux de Marseille | Marseille, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07049588